In a real-world cohort including data of >60,000 AF ablation procedures performed between 2010-2015, early mortality rate was 0.46%. Strongest predictors for early mortality were procedural complications, CHF and low AF ablation hospital volume.
In a Danish cohort study of nonvalvular AF patients, DOAC use was associated with a lower risk of osteoporotic fractures compared to VKA treatment.
CSI Paris Tine Proesmans explains how screening for AF can be done in the general population using a smartphone and shares results of the DIGITAL-AF II study.
A meta-analysis of RE-DUAL PCI, PIONEER AF-PCI and AUGUSTUS compared NOAC- and VKA-based regimens and antithrombotic therapies with and without aspirin for ischemic outcomes and CV and total mortality.
Data of the Framingham Original and Offspring Cohorts show that parental smoking during childhood is associated with a higher AF risk, partly because offspring show higher propensity of smoking.
Large community-based study with repeated weight and height measurements shows that long-term obesity and change in BMI over time are more informative to assess AF risk than current weight.
ESC 2019 Prof. Verheugt talks about the results of the AFIRE trial, in which monotherapy with rivaroxaban was compared with a combination therapy of rivaroxaban and antiplatelet agents in CAD patients with AF.
An AI model permits point-of-care identification of individuals with a high likelihood of AF, in normal sinus rhythm ECGs, based on subtle findings due to structural changes in the atria.
In a subanalysis of the ENGAGE AF-TIMI 48 study, efficacy and safety of high dose edoxaban was similar in AF patients with and without liver disease.
In the CABANA trial, catheter ablation did not result in a reduction of death, disabling stroke, serious bleeding or cardiac arrest in symptomatic AF patients compared to drug therapy.
A wait-and-see strategy with rate-control drugs was non-inferior to early pharmacologic or electric conversion in achieving sinus rhythm among patients with recent-onset symptomatic AF.
ACC 2019 Dr. John Alexander summarizes the main findings of the AUGUSTUS trial, in which apixaban yielded better results than warfarin, and those not on aspirin did better than those taking aspirin, in patients with AF and a recent ACS/PCI.